Identification of the HSP70 peptide for the development of cancer immunetherapy

2015 Fiscal Year Final Research Report

• Project/Area Number: 26670606
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Digestive surgery
• Research Institution: Yamaguchi University
• Principal Investigator: OKA Masaaki 山口大学, その他部局等, 学長 (70144946)
• Co-Investigator(Kenkyū-buntansha): YOSHIMURA Kiyoshi 国立がん研究センター, 先端医療開発センター・免疫療法開発分野, 分野長 (30346564) ; TSUNEDOMI Ryouichi 山口大学, 大学院医学系研究科, 助教 (10420514)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: 肝細胞癌 / ワクチン療法

Outline of Final Research Achievements

We identified the Heat Shock Protein (HSP) 70 as a specific antigen of hepatocellular carcinoma. Furthermore, the phase I study of HSP70-mRNA introduced dendritic cells therapy showed the safety and efficacy. In this study, we tried to identify the HSP70 peptide sequence, which can induce the anti-tumor response, in order to the development of useful peptide vaccine therapy for cancer. Candidate HSP70 peptides predicted as multi-HLA binding potency were confirmed by ELISpot assay and ELISA for IFN-gamma production. The safty of the peptides were examined in rats and dogs. We started a clinical trial of first in Human HSP70 peptide immunetherapy for several cancers.

Free Research Field

消化器外科